Sagimet Biosciences Inc. Financials
This page shows Sagimet Biosciences Inc. (SGMT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Sagimet Biosciences Inc. passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
For every $1 of reported earnings, Sagimet Biosciences Inc. generates $0.93 in operating cash flow (-$42.4M OCF vs -$45.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Sagimet Biosciences Inc. reported -$45.6M in net income in fiscal year 2024. This represents a decrease of 63.5% from the prior year.
Sagimet Biosciences Inc. earned $-1.45 per diluted share (EPS) in fiscal year 2024. This represents an increase of 45.5% from the prior year.
Sagimet Biosciences Inc. held $75.8M in cash against $0 in long-term debt as of fiscal year 2024.
Sagimet Biosciences Inc. invested $38.4M in research and development in fiscal year 2024. This represents an increase of 94.4% from the prior year.
SGMT Income Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $2.0M | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $9.7M-23.1% | $12.7M | N/A | $5.0M | N/A | $6.8M |
| SG&A Expenses | $4.6M+8.4% | $4.2M | N/A | $4.5M | N/A | $848K |
| Operating Income | -$14.3M+15.2% | -$16.9M | N/A | -$7.5M | N/A | -$7.7M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$12.9M+11.7% | -$14.6M | N/A | -$6.4M | N/A | -$7.5M |
| EPS (Diluted) | $-0.40+11.1% | $-0.45 | N/A | $-0.35 | N/A | $-40.34 |
SGMT Balance Sheet
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|
| Total Assets | $128.4M-19.9% | $160.3M+65.7% | $96.7M-6.0% | $102.9M+211.6% | $33.0M | N/A |
| Current Assets | $119.5M-21.8% | $152.8M+58.1% | $96.6M-6.0% | $102.8M+213.5% | $32.8M | N/A |
| Cash & Equivalents | $32.5M-57.2% | $75.8M+0.9% | $75.1M-26.2% | $101.8M+64357.0% | $158K-92.9% | $2.2M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $9.1M+105.3% | $4.5M-21.2% | $5.7M+12.0% | $5.0M-97.7% | $220.0M | N/A |
| Current Liabilities | $9.1M+105.3% | $4.5M-21.2% | $5.7M+12.0% | $5.0M-4.4% | $5.3M | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $119.3M-23.5% | $155.8M+71.1% | $91.1M-7.0% | $97.9M+152.4% | -$186.9M-3.5% | -$180.6M |
| Retained Earnings | -$336.8M-14.0% | -$295.3M-18.2% | -$249.7M-3.4% | -$241.6M-8.9% | -$221.9M | N/A |
SGMT Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$10.2M+7.7% | -$11.0M-55.6% | -$7.1M-82.6% | -$3.9M+48.0% | -$7.5M-19.6% | -$6.2M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $75K-99.2% | $9.8M+150.2% | -$19.6M | $0-100.0% | $5.4M+35.9% | $4.0M |
| Financing Cash Flow | $274K | $0 | $0-100.0% | $87.2M+158669.1% | -$55K | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A |
SGMT Financial Ratios
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | -372.6% | N/A | N/A |
| Net Margin | N/A | N/A | N/A | -317.6% | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -10.1%-1.7pp | -8.4% | N/A | -6.2% | N/A | N/A |
| Current Ratio | 13.06-21.2 | 34.30+17.2 | 17.09-3.3 | 20.36+14.2 | 6.21 | N/A |
| Debt-to-Equity | 0.08+0.0 | 0.03-0.0 | 0.06+0.0 | 0.05+1.2 | -1.18 | N/A |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Sagimet Biosciences Inc. profitable?
No, Sagimet Biosciences Inc. (SGMT) reported a net income of -$45.6M in fiscal year 2024.
What is Sagimet Biosciences Inc.'s earnings per share (EPS)?
Sagimet Biosciences Inc. (SGMT) reported diluted earnings per share of $-1.45 for fiscal year 2024. This represents a 45.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Sagimet Biosciences Inc.'s operating cash flow?
Sagimet Biosciences Inc. (SGMT) generated -$42.4M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Sagimet Biosciences Inc.'s total assets?
Sagimet Biosciences Inc. (SGMT) had $160.3M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Sagimet Biosciences Inc. spend on research and development?
Sagimet Biosciences Inc. (SGMT) invested $38.4M in research and development during fiscal year 2024.
What is Sagimet Biosciences Inc.'s current ratio?
Sagimet Biosciences Inc. (SGMT) had a current ratio of 34.30 as of fiscal year 2024, which is generally considered healthy.
What is Sagimet Biosciences Inc.'s debt-to-equity ratio?
Sagimet Biosciences Inc. (SGMT) had a debt-to-equity ratio of 0.03 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Sagimet Biosciences Inc.'s return on assets (ROA)?
Sagimet Biosciences Inc. (SGMT) had a return on assets of -28.4% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Sagimet Biosciences Inc.'s cash runway?
Based on fiscal year 2024 data, Sagimet Biosciences Inc. (SGMT) had $75.8M in cash against an annual operating cash burn of $42.4M. This gives an estimated cash runway of approximately 21 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Sagimet Biosciences Inc.'s Piotroski F-Score?
Sagimet Biosciences Inc. (SGMT) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Sagimet Biosciences Inc.'s earnings high quality?
Sagimet Biosciences Inc. (SGMT) has an earnings quality ratio of 0.93x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.